ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
71,330.71
-0.16%
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
0.00%
US Dollar vs Yen
156.2935
-0.05%
Brent Oil
82.26
-1.52%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Nabriva Therapeutics PLC (NBRV)

  7. Nabriva Therapeutics PLC (NBRV) ニュース

NBRV

Nabriva Therapeutics (NBRV)

Nabriva Therapeutics PLC
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:NBRV
日付受信時刻ニュースソース見出しコード企業名
2023/10/2602 : 43Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:NBRVNabriva Therapeutics PLC
2023/10/2513 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBRVNabriva Therapeutics PLC
2023/10/2010 : 01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NBRVNabriva Therapeutics PLC
2023/10/2009 : 22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBRVNabriva Therapeutics PLC
2023/07/3121 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
2023/07/2422 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
2023/07/1106 : 49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NBRVNabriva Therapeutics PLC
2023/07/1105 : 01GlobeNewswire Inc.Arbutus Appoints Two New ExecutivesNASDAQ:NBRVNabriva Therapeutics PLC
2023/07/0805 : 34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
2023/06/0205 : 31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
2023/05/2305 : 02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NBRVNabriva Therapeutics PLC
2023/05/1606 : 25Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:NBRVNabriva Therapeutics PLC
2023/04/0105 : 30Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:NBRVNabriva Therapeutics PLC
2023/01/2020 : 05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
2023/01/1107 : 59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
2023/01/1107 : 57Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
2023/01/0621 : 01GlobeNewswire Inc.Nabriva Therapeutics Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
2023/01/0508 : 10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
2023/01/0508 : 09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
2022/12/0906 : 38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
2022/12/0307 : 18Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
2022/11/2920 : 30TipRanksAnalysts Conflicted on These Healthcare Names: Nabriva (NBRV), Vir Biotechnology (VIR) and Greenwich LifeSciences (GLSI)NASDAQ:NBRVNabriva Therapeutics PLC
2022/11/2821 : 01GlobeNewswire Inc.Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNASDAQ:NBRVNabriva Therapeutics PLC
2022/11/1106 : 12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
2022/11/1106 : 07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NBRVNabriva Therapeutics PLC
2022/11/1106 : 01GlobeNewswire Inc.Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
2022/11/0907 : 27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
2022/11/0721 : 01GlobeNewswire Inc.Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022NASDAQ:NBRVNabriva Therapeutics PLC
2022/11/0206 : 09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
2022/10/0505 : 05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:NBRV

最近閲覧した銘柄

NYSE
JPM
JP Morgan Chase
CCOM
SILVER
SILVER
NYSE
MRK
Merck
CCOM
US30
US 30
AMEX
XLV
Health Care Select Sector
USI
USTECH100
US Tech 100
SPI
SP500
S&P 500
USOTC
BASFY
BASF (QX)
NYSE
XOM
Exxon Mobil
NYSE
MCD
McDonalds
NASDAQ
AAPL
Apple
AMEX
XLF
Financial Select Sector
COIN
SOLUSD
Solana
NASDAQ
GOOGL
Alphabet
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有